Ann: Imugene appoints Dr Jakob Dupont as Non-Executive Director, page-34

hi Dave @davybabyk

Always enjoy and learn something new from your posts.

Indeed, many things aren’t zero sum. The BIG DAY for some of us to put a face to a person is worth waiting for, and it won’t be too far off given AI or modern advanced computing is helping reducing overall trial time significantly ! eg, HER-Vaxx dosing started in July 2017 and took us 5 years to finalise the promising final OS in 2022 very recently, but VAXINIA CF33 will receive OS data 24 months from the 1st dose in May 2022, ie, around May 2024 ! Other markers too, like DOR, DCR. Pls ref to NCT05346484 @clinical trials.gov. Kindly correct me if I’m wrong. as per her interviews lately on early promising signals, there is every reason to be as positive as Leslie and all the professors, clinicians, scientists, and those private oncologists I seeking approval and wanting to partner with Imugene’s immuno therapies trials. DYOR pls

I am enjoying the serenity of a smallish town near Liverpool/Manchester. Should be heading back to Guildford after another visit to the Peak and Lake Districts

Kluck